Chemotherapy is considered “state of the art” for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor activity.
Carcinoma, Neuroendocrine, Stomach Neoplasms, Neoplasm Metastases, Medical Oncology
Delle FaveG, O′'TooleD, SundinA, et al. ENETS Consensus Conference participants: ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119-24. [PMID:26784901] [https://doi.org/10.1159/000443168].
RindiG, ArnoldR, BosmanFT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: BosmanFT, CarneiroF, HrubanRH, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. 13-145.
PapeUF, JannH, Muller-NordhornJ, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256-65. [PMID:18506737] [https://doi.org/10.1002/cncr.23549].
KimHK, HaSY, LeeJ, et al. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget. 2017;8(43):73974-80. [PMID:29088761]
SorbyeH, WelinS, LangerSW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO grade 3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152-60. [PMID:22967994] [https://doi.org/10.1093/annonc/mds276].
HenticO, HammelP, CouvelardA, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751-7. [PMID:22940375] [https://doi.org/10.1530/ERC-12-0002].